Please assess the completion status of the following clinical trial:

Trial Title: Minocycline for HIV+ Cognitive Impairment in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection prior to study entry~* Naïve to any antiretroviral regimen and ineligible to receive antiretroviral therapy by cluster of differentiation 4 (CD4) criteria in Uganda~* Negative serum or urine pregnancy test for women of childbearing potential~* Willingness to use birth control~* Age 18-65 years~* AIDS Dementia Scale Stage 0.5 OR 1~* Impaired cognitive performance as evidenced by an International HIV Dementia Scale (HDS) as defined by the protocol~* Ability to sit or stand and swallow intact capsules with an 8-ounce glass of water~* Ability and willingness of subject or legal guardian/ representative to give written informed consent~* Resident within a 20km radius of Kampala city~Exclusion Criteria:~* Current cancers other than basal cell carcinoma, in situ carcinoma of the cervix, or Kaposi's sarcoma without evidence of visceral involvement or which does not require systemic chemotherapy~* Severe premorbid psychiatric illness, including schizophrenia and major depression which, in the in investigator's opinion, is likely to interfere with study compliance~* Active symptomatic AIDS-defining opportunistic infection within 45 days prior to study entry~* Confounding neurological disorders as defined in the protocol~* Central nervous system infections or cancers as defined in the protocol~* Systemic lupus~* Thyroid disease diagnosed within 24 weeks prior to entry~* Breastfeeding~* Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements~* Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator~* History of allergy/sensitivity to minocycline or other tetracyclines and their formulations~* Any other clinically significant condition or laboratory abnormality that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study. This includes an individual found to have an HIV dementia scale stage 3 or 4.~* Any esophageal or other condition that would interfere with the swallowing of the study medication~* Use of excluded drugs as defined by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: ACTIVE_COMPARATOR): Minocycline 100 mg orally every 12 hours
- Placebo (Type: PLACEBO_COMPARATOR): Placebo minocycline capsules every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).